Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
Discontinuation of RLYB212 Program: Rallybio Corporation has decided to discontinue the RLYB212 program for preventing fetal and neonatal alloimmune thrombocytopenia due to Phase 2 trial results showing it did not achieve necessary pharmacokinetic concentrations for efficacy.
Focus on RLYB116 Development: The company is advancing its RLYB116 program, a C5 inhibitor, with plans to initiate a confirmatory PK/PD study in Q2 2025, aiming to address complement-mediated diseases and deliver data by late 2025.
Trade with 70% Backtested Accuracy
Analyst Views on RLYB
About RLYB
About the author
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
InflaRx N.V. Surge: InflaRx N.V. saw a significant after-hours increase of 63.41% to $2.01, driven by the anticipation of topline data from its Phase 2a trial and third-quarter financial results expected on Monday.
Rallybio Corp. Performance: Rallybio Corp. rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, reversing a loss from the previous year, although revenue slightly declined.
FibroBiologics Inc. Growth: FibroBiologics Inc. climbed 13.51% to $0.40 after hours, following a previous corporate update and third-quarter financial results released on October 31.
Cellectis S.A. Recovery: Cellectis S.A. increased by 6.58% to $3.40 after reporting a third-quarter net income of $589 thousand, a significant improvement from a loss in the prior year, with revenues more than doubling.
Rallybio Announces Financial Results for Q3 2025 and Shares Business Developments
RLYB116 Study Progress: Rallybio has completed dosing for Cohort 1 in the RLYB116 Phase 1 confirmatory PK/PD study, with data expected in Q4 2025, targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome.
Financial Highlights: The company generated $20 million from the sale of its interest in REV102, extending its cash runway through 2027, and reported a net income of $16 million for Q3 2025, a significant improvement from a net loss in the same period last year.
Post-Market Activity: Biotech and Medtech Stocks Surge on Increased Volume and Announcements
Biotech Stock Movements: Several biotech and medical device stocks experienced significant after-hours gains, with Reviva Pharmaceuticals (RVPH) leading the surge with an 18.27% increase, driven by high trading volume and recent catalysts related to its lead candidate brilaroxazine.
Company Updates and Guidance: Penumbra Inc. (PEN) and Palisade Bio Inc. (PALI) also saw notable increases, with PEN benefiting from executive changes and positive revenue guidance, while PALI's rise was linked to a successful public offering and clinical updates.
Rallybio Finishes Dosing Initial Group in Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study for RLYB116
RLYB116 Study Progress: Rallybio Corporation has completed dosing for the first cohort in a Phase 1 study of RLYB116, a C5 inhibitor, showing promising pharmacokinetic and pharmacodynamic results, along with a favorable safety profile.
Future Plans and Market Potential: The company plans to escalate dosing to a second cohort and aims to target two hematologic conditions, immune platelet transfusion refractoriness and refractory antiphospholipid syndrome, which present a combined market opportunity of $5 billion.
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
Rallybio's Agreement with Recursion Pharmaceuticals: Rallybio has agreed to sell its interest in the preclinical drug REV102 to Recursion Pharmaceuticals for up to $25 million, which includes an upfront payment of $7.5 million and potential milestone payments.
Financial Impact on Rallybio: The deal is expected to extend Rallybio's cash runway into mid-2027, and they will also receive royalties on future sales of REV102 by Recursion.
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Rallybio Corporation's Sale of REV102: Rallybio has agreed to sell its interest in the ENPP1 inhibitor REV102 to Recursion Pharmaceuticals for up to $25 million, which includes an upfront payment of $7.5 million, extending Rallybio's cash runway into mid-2027.
Impact on Stock Prices: Following the announcement, Rallybio's stock rose by 36.8% to $0.47, while Recursion's stock increased by 0.81% to $4.97 during premarket trading.
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
InflaRx N.V. Surge: InflaRx N.V. saw a significant after-hours increase of 63.41% to $2.01, driven by the anticipation of topline data from its Phase 2a trial and third-quarter financial results expected on Monday.
Rallybio Corp. Performance: Rallybio Corp. rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, reversing a loss from the previous year, although revenue slightly declined.
FibroBiologics Inc. Growth: FibroBiologics Inc. climbed 13.51% to $0.40 after hours, following a previous corporate update and third-quarter financial results released on October 31.
Cellectis S.A. Recovery: Cellectis S.A. increased by 6.58% to $3.40 after reporting a third-quarter net income of $589 thousand, a significant improvement from a loss in the prior year, with revenues more than doubling.
Rallybio Announces Financial Results for Q3 2025 and Shares Business Developments
RLYB116 Study Progress: Rallybio has completed dosing for Cohort 1 in the RLYB116 Phase 1 confirmatory PK/PD study, with data expected in Q4 2025, targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome.
Financial Highlights: The company generated $20 million from the sale of its interest in REV102, extending its cash runway through 2027, and reported a net income of $16 million for Q3 2025, a significant improvement from a net loss in the same period last year.
Post-Market Activity: Biotech and Medtech Stocks Surge on Increased Volume and Announcements
Biotech Stock Movements: Several biotech and medical device stocks experienced significant after-hours gains, with Reviva Pharmaceuticals (RVPH) leading the surge with an 18.27% increase, driven by high trading volume and recent catalysts related to its lead candidate brilaroxazine.
Company Updates and Guidance: Penumbra Inc. (PEN) and Palisade Bio Inc. (PALI) also saw notable increases, with PEN benefiting from executive changes and positive revenue guidance, while PALI's rise was linked to a successful public offering and clinical updates.
Rallybio Finishes Dosing Initial Group in Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study for RLYB116
RLYB116 Study Progress: Rallybio Corporation has completed dosing for the first cohort in a Phase 1 study of RLYB116, a C5 inhibitor, showing promising pharmacokinetic and pharmacodynamic results, along with a favorable safety profile.
Future Plans and Market Potential: The company plans to escalate dosing to a second cohort and aims to target two hematologic conditions, immune platelet transfusion refractoriness and refractory antiphospholipid syndrome, which present a combined market opportunity of $5 billion.
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
Rallybio's Agreement with Recursion Pharmaceuticals: Rallybio has agreed to sell its interest in the preclinical drug REV102 to Recursion Pharmaceuticals for up to $25 million, which includes an upfront payment of $7.5 million and potential milestone payments.
Financial Impact on Rallybio: The deal is expected to extend Rallybio's cash runway into mid-2027, and they will also receive royalties on future sales of REV102 by Recursion.
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Rallybio Corporation's Sale of REV102: Rallybio has agreed to sell its interest in the ENPP1 inhibitor REV102 to Recursion Pharmaceuticals for up to $25 million, which includes an upfront payment of $7.5 million, extending Rallybio's cash runway into mid-2027.
Impact on Stock Prices: Following the announcement, Rallybio's stock rose by 36.8% to $0.47, while Recursion's stock increased by 0.81% to $4.97 during premarket trading.
